The Clinical Trials Support Office (CTSO) was established in 2002 to provide support for clinical researchers at the three Fred Hutchinson/University of Washington Cancer Consortium (Consortium) institutions, which are Fred Hutchinson Cancer Research Center (FHCRC), University of Washington (UW), and Children's Hospital and Regional Medical Center (Children's). The overarching goal of the CTSO is to provide the infrastructure to support the conduct of efficient, high-quality, regulatorycompliant clinical trials within the Consortium. Toward this end, the CTSO provides centralized training and education to Cancer Consortium members and research staff on appropriate conduct of clinical trials. The CTSO also provides, on a fee-for-service basis, research study staff to implement and manage all aspects of clinical trials. The CTSO is responsible for the clinical trials monitoring program and for Protocol-Specific Research Support activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-39
Application #
8562017
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
39
Fiscal Year
2013
Total Cost
$310,205
Indirect Cost
$118,327
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Morris, S M; Carter, K T; Baek, J Y et al. (2015) TGF-? signaling alters the pattern of liver tumorigenesis induced by Pten inactivation. Oncogene 34:3273-82
Briant, Katherine Josa; Espinoza, Noah; Galvan, Avigail et al. (2015) An innovative strategy to reach the underserved for colorectal cancer screening. J Cancer Educ 30:237-43
Toledo, Chad M; Herman, Jacob A; Olsen, Jonathan B et al. (2014) BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Dev Cell 28:282-94
Klippel, Z K; Chou, J; Towlerton, A M et al. (2014) Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 21:337-42
Mielcarek, Marco; Kirkorian, Anna Yasmine; Hackman, Robert C et al. (2014) Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation. Transplantation 98:563-8
Luo, Yanxin; Wong, Chao-Jen; Kaz, Andrew M et al. (2014) Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147:418-29.e8
Cermelli, Silvia; Jang, In Sock; Bernard, Brady et al. (2014) Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med 4:
Rizzardi, Anthony E; Rosener, Nikolaus K; Koopmeiners, Joseph S et al. (2014) Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 14:244
Vainstein, V; Buckley, S A; Shukron, O et al. (2014) Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 28:713-6
Laszlo, George S; Ries, Rhonda E; Gudgeon, Chelsea J et al. (2014) High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma 55:2817-21

Showing the most recent 10 out of 300 publications